Radiesse™ calcium hydroxylapatite injectable filler

In December 2006, the Food and Drug Administration approved calcium hydroxylapatite (CaHA) as an injectable dermal filler for the correction of moderate to severe facial wrinkles and treatment for HIV lipoatrophy. Radiesse is often well received as a suggested filler because its primary active constituent, Calcium, is familiar to people and considered to be beneficial to overall health. Bruising is a potential side effect of any injection and Radiesse treatments are no exception. Radiesse, as a particulate injectable, has a risk of embolization if inadvertently injected in this fashion and complications such as vision loss or even blindness could occur in certain locations. Nasal irregularities such as a deep radix can be improved with Radiesse though great caution must be taken to prevent intravascular injection of the material with the risks of embolization and complications.